Selected research
Industry Growth & Trends
Global Antisense and RNAi Therapeutics Drug Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Antisense and RNAi Therapeutics Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Antisense and RNAi Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Antisense and RNAi Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antisense and RNAi Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Antisense and RNAi Therapeutics Drug market include Biogen, Sarepta Therapeutics, Kastle therapeutics, Jazz Pharmaceuticals, Dynavax Technologies, Bausch & Lomb, Alnylam Pharmaceuticals and Akcea Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Antisense and RNAi Therapeutics Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Antisense and RNAi Therapeutics Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antisense and RNAi Therapeutics Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antisense and RNAi Therapeutics Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Antisense and RNAi Therapeutics Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Antisense and RNAi Therapeutics Drug Market by Company
Biogen
Sarepta Therapeutics
Kastle therapeutics
Jazz Pharmaceuticals
Dynavax Technologies
Bausch & Lomb
Alnylam Pharmaceuticals
Akcea Therapeutics
Antisense and RNAi Therapeutics Drug Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Antisense and RNAi Therapeutics Drug Segment by Application
ATTR
Hepatic VOD
Neuromuscular Diseases
Other
Antisense and RNAi Therapeutics Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Antisense and RNAi Therapeutics Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Antisense Oligonucleotide
- Aptamer
- Other
Applications
- ATTR
- Hepatic VOD
- Neuromuscular Diseases
- Other
Companies covered
- Biogen
- Sarepta Therapeutics
- Kastle therapeutics
- Jazz Pharmaceuticals
- Dynavax Technologies
- Bausch & Lomb
- Alnylam Pharmaceuticals
- Akcea Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Antisense and RNAi Therapeutics Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Antisense and RNAi Therapeutics Drug Market Size by Region (2021-2032)
- 1.4.1 Global Antisense and RNAi Therapeutics Drug Market Size by Region (2021-2026)
- 1.4.2 Global Antisense and RNAi Therapeutics Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
- 1.5.1 North America Antisense and RNAi Therapeutics Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Antisense and RNAi Therapeutics Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Antisense and RNAi Therapeutics Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size Growth Rate (2021-2032)
2 Antisense and RNAi Therapeutics Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Antisense Oligonucleotide
- 2.1.2 Aptamer
- 2.1.3 Other
- 2.2 Global Antisense and RNAi Therapeutics Drug Market Size by Type
- 2.2.1 Global Antisense and RNAi Therapeutics Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Antisense and RNAi Therapeutics Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Antisense and RNAi Therapeutics Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Antisense and RNAi Therapeutics Drug Market Size by Regions
- 2.3.1 North America Antisense and RNAi Therapeutics Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Antisense and RNAi Therapeutics Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Antisense and RNAi Therapeutics Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Antisense and RNAi Therapeutics Drug Market Size Breakdown by Type (2021-2026)
3 Antisense and RNAi Therapeutics Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 ATTR
- 3.1.2 Hepatic VOD
- 3.1.3 Neuromuscular Diseases
- 3.1.4 Other
- 3.2 Global Antisense and RNAi Therapeutics Drug Market Size by Application
- 3.2.1 Global Antisense and RNAi Therapeutics Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Antisense and RNAi Therapeutics Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Antisense and RNAi Therapeutics Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Antisense and RNAi Therapeutics Drug Market Size by Regions
- 3.3.1 North America Antisense and RNAi Therapeutics Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Antisense and RNAi Therapeutics Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Antisense and RNAi Therapeutics Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Antisense and RNAi Therapeutics Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Antisense and RNAi Therapeutics Drug Industry Trends
- 4.2 Antisense and RNAi Therapeutics Drug Industry Drivers
- 4.3 Antisense and RNAi Therapeutics Drug Industry Opportunities and Challenges
- 4.4 Antisense and RNAi Therapeutics Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Antisense and RNAi Therapeutics Drug Revenue (2021-2026)
- 5.2 Global Antisense and RNAi Therapeutics Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Antisense and RNAi Therapeutics Drug Key Company Headquarters & Area Served
- 5.4 Global Antisense and RNAi Therapeutics Drug Company, Product Type & Application
- 5.5 Global Antisense and RNAi Therapeutics Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Antisense and RNAi Therapeutics Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Antisense and RNAi Therapeutics Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Antisense and RNAi Therapeutics Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Biogen
- 6.1.1 Biogen Company Information
- 6.1.2 Biogen Business Overview
- 6.1.3 Biogen Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Biogen Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.1.5 Biogen Recent Developments
- 6.2 Sarepta Therapeutics
- 6.2.1 Sarepta Therapeutics Company Information
- 6.2.2 Sarepta Therapeutics Business Overview
- 6.2.3 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.2.5 Sarepta Therapeutics Recent Developments
- 6.3 Kastle therapeutics
- 6.3.1 Kastle therapeutics Company Information
- 6.3.2 Kastle therapeutics Business Overview
- 6.3.3 Kastle therapeutics Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Kastle therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.3.5 Kastle therapeutics Recent Developments
- 6.4 Jazz Pharmaceuticals
- 6.4.1 Jazz Pharmaceuticals Company Information
- 6.4.2 Jazz Pharmaceuticals Business Overview
- 6.4.3 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.4.5 Jazz Pharmaceuticals Recent Developments
- 6.5 Dynavax Technologies
- 6.5.1 Dynavax Technologies Company Information
- 6.5.2 Dynavax Technologies Business Overview
- 6.5.3 Dynavax Technologies Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Dynavax Technologies Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.5.5 Dynavax Technologies Recent Developments
- 6.6 Bausch & Lomb
- 6.6.1 Bausch & Lomb Company Information
- 6.6.2 Bausch & Lomb Business Overview
- 6.6.3 Bausch & Lomb Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Bausch & Lomb Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.6.5 Bausch & Lomb Recent Developments
- 6.7 Alnylam Pharmaceuticals
- 6.7.1 Alnylam Pharmaceuticals Company Information
- 6.7.2 Alnylam Pharmaceuticals Business Overview
- 6.7.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.7.5 Alnylam Pharmaceuticals Recent Developments
- 6.8 Akcea Therapeutics
- 6.8.1 Akcea Therapeutics Company Information
- 6.8.2 Akcea Therapeutics Business Overview
- 6.8.3 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
- 6.8.5 Akcea Therapeutics Recent Developments
7 North America
- 7.1 North America Antisense and RNAi Therapeutics Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 7.3 North America Antisense and RNAi Therapeutics Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Antisense and RNAi Therapeutics Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 8.3 Europe Antisense and RNAi Therapeutics Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Antisense and RNAi Therapeutics Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 10.3 South America Antisense and RNAi Therapeutics Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst